Scottish HTA body OKs Lynparza For Earlier Use In Ovarian Cancer
Move Follows NICE Recommendation For England In July
AstraZeneca’s Lynparza can now be used on the Scottish National Health Service for newly diagnosed advanced ovarian cancer.
You may also be interested in...
AstraZeneca and MSD's Lynparza can now be paid for through England’s Cancer Drugs Fund for use in women with advanced BRCA-mutated ovarian cancer when their disease is newly diagnosed and when the drug may have the potential to cure their disease.
Coronavirus Notebook: EU Agencies Update On ‘Mix-And-Match’ & Booster Vaccines, UK Expands Human Challenge Trial
ExeVir’s potential antibody therapy against variants of concern is moving into clinical trials, and Irish researchers say an abandoned glioblastoma candidate compound could prevent respiratory and cardiovascular damage in COVID-19 patients.
Legislation that will help to build a future “European Health Union” is making its way through the EU legislative process. It includes a greater role for EU health agencies in making preparations for future health emergencies.